LTR PHARMA LIMITED - Key Persons

Job Titles:

• Member of the Key Management Team
• VP Commercial

Danny has over 25 years of commercial experience in Australian and global pharmaceuticals and medical devices. He has held executive positions in both private and ASX listed entities including Admedus Ltd, Roche and Actelion with a track record of successfully commercialising new medical technologies in Europe, North America, Asia Pacific and MENA.

Job Titles:

• Independent Non - Executive Director
• Member of the Board of Directors
• Healthcare Executive

Julian is an experienced healthcare executive with over 20 years' experience in board and senior management positions, including ASX listed companies Avexa (ASX.AVX), Admedus (ASX.AHZ), and is current Deputy Chairman of Cann Group Limited (ASX:CAN). Julian's experience includes working across investment banking transactions for over eight years, focused on reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists.

Job Titles:

• Member of the Key Management Team
• VP, Operations & Clinical Development

Monil has over 20 years of pharmaceutical and biotechnology industry experience in drug development. His most recent appointments include Chief Business Officer at Imugene and Chief Development Officer at WindMIL Therapeutics, and Chief Operating Officer of IRX Therapeutics. Previously, Medical Affairs Lead for Immuno-Oncology at Bristol Myers Squibb.

Job Titles:

• Consultant

Professor Eric Chung is a consultant urological surgeon at the AndroUrology Centre for Sexual, Urinary and Reproductive Excellence and holds professorial academic appointments at the University of Queensland in Brisbane and Macquarie University Hospital in Sydney. He is the Secretary-General of the Asia Pacific Society of Sexual Medicine (APSSM), Past Chair of the Andrology section within the Urological Society of Australia and New Zealand (USANZ) and Chair of the Scientific Committee at the International Society of Sexual Medicine (ISSM). He has been invited as speaker and surgeon mentor at many national and international meetings, and has authored more than 130 peer-reviewed papers and book chapters.

Job Titles:

• Chief Financial Officer
• Member of the Key Management Team

Jacques brings over 14 years of experience in Finance, Commercial Management & Controller roles. Prior to LTP he has been in senior financial roles at Lion Dairy & Drinks, Anteris Technologies, NL Food, First Quantum Minerals as well having successfully owned and managed several private businesses.

Job Titles:

• Member of the Key Management Team
• VP, Regulatory

Kip is a senior pharmaceutical R&D and regulatory executive with over 25 years of experience across major global markets. Successful leadership in preparation of agency meetings (PIND and equivalent, EOP1, EOP2, and PNDA/MAA and regional equivalents) all the way through to the preparation and submission of market applications.

Job Titles:

• Executive Chairman
• Executive Chairman of the Board of Directors

Lee holds over 25 years' experience in the healthcare and technology sectors and has been in executive leadership roles in both Public and Private enterprises. He previously worked in Fortescue Metals Group and led a healthcare technology spin out (Allied Medical) as its CEO and Managing Director that resulted in increasing its valuation from $800k to a peak of $250m (ASX:AHZ, AVR). He was also the Senior Executive of Sirius Minerals Plc that led to its lead acquisition project and reached a peak market capitalisation of over $1 billion on the London exchange. Lee holds an MBA from the University of St Thomas, Minnesota and B.A. degree in Business Management from St John's University. Lee holds over 25 years' experience in healthcare and technology sectors in both public ASX and private enterprises, holding multiple executive leadership roles. Prior to joining LTR Pharma, Lee worked at Fortescue Metals group and was CEO and managing director for healthcare technology spin out Allied Medical, leading it to a valuation peak of $250m from $800k. Lee has a proven record of commercialising medical devices in Australia, North America, Europe and Asia with significant experience in Nasal Spray product sales

Job Titles:

• Member of the Key Management Team
• VP, US Sales & Marketing

Mike has over 30 years of senior leadership roles in the pharmaceutical industry in commercial sales and market access. Mike currently serves early-stage pharmaceutical and biotech companies as an executive management consultant, most recently, building all functions related to Market Access for Scilex Pharmaceuticals, a San Diego-based startup.

Job Titles:

• Independent Non - Executive Director
• Member of the Board of Directors

Maja is a consulting lawyer and board director with a 15-year track record of providing strategic, corporate and compliance advice to public listed companies. This includes working with listed companies as a non-executive chair, non-executive director, general counsel, company secretary and in private practice. Prior to joining LTR Pharma, Maja was general counsel and company secretary of US based Alexium International Group Limited (ASX:AJC). Maja currently holds roles in multiple ASX listed companies, including non-executive chair of TechGen Metals (ASX.TG1), non-executive director of Kuniko (ASX.KNI), non-executive director of Indiana Resources Liimited (ASX.IDA).

Job Titles:

• Chief Operating Officer
• Member of the Key Management Team

Peter has worked with companies of all sizes worldwide to improve operations and technology and engage with the financial markets. Peter has advised large European enterprises, Australian and New Zealand startups, and Australian government agencies. Peter has also served as a Non-Executive Director on an ASX board for a technology company, bringing valuable insights into governance and strategic direction. Furthermore, Peter worked in London for a US investment bank and as a consultant to Life Science, Agricultural, Industrial, and Technology companies in Australia, giving him extensive financial markets and M&A experience.

Job Titles:

• Member of the Key Management Team
• Health Researcher Who Has Specialist
• Medical Affairs Executive

Prof. Geoff Strange is a health researcher who has specialist interest in "Big Data", Artificial Intelligence (AI) and its application to further our understanding of a variety of Structural Heart Disease. Geoff is Professor within the Faculty of Medicine and Health at the University of Sydney and the School of Medicine, University of Notre Dame, Australia. Geoff is the Senior Academic lead for the burden of disease study (CHD) base at the Heart Research Institute Sydney and is a member of the cardiology research team at Royal Prince Alfred Hospital, Sydney. Geoff is creator, Director and Chief Investigator of the National Echo Database of Australia and New Zealand (NEDA) - the largest mortality linked echocardiographic database in the world covering more than 45 specialist centres across Australia. Geoff has led several governmental initiatives that have resulted in significant translational outcomes for patients (including combination therapy funding for PAH and the National Action Plan on childhood heart disease after establishing the Congenial Heart Alliance of Australia and New Zealand; a research initiative spanning 15 centres across the region resulting in 27 M in funding for the National Action Plan on childhood heart disease from The Hon Minister Hunt). Geoff's research interests include, Big Data and AI for Cardiovascular Disease (Structural Heart Disease), Pulmonary Hypertension, Congenital Heart Disease and Echocardiography. Geoffrey is a senior executive and medical researcher with over 20 years' experience in the biopharmaceutical and medical industries. He's been an expert scientific advisor for numerous global pharmaceutical companies including Pfizer, Novartis, Bayer Pharmaceuticals Australia, Glaxo Smith & Kline (GSK) Australia and Edwards LifeSciences.

Job Titles:

• Director of the Centre for Urology Research

Professor Russ Chess-Williams is the Director of the Centre for Urology Research and Professor of Pharmacology at Bond University. His main research interests are the physiology and pharmacology of the lower urinary tract and he was involved in the early pre-clinical studies of tamsulosin, solifenacin and mirabegron. His recent studies have focused on the role of the urothelium in regulating lower urinary tract function and bladder sensory mechanisms in health and disease. He has published >170 papers that have received >8500 citations and he has authored >600 conference abstracts. His published works include original papers in European Urology (IF=17) and Nature (IF=43) and his publications have been referenced in 26 patents.